Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

Star Scientific Defends Ariva As “Compressed Version” Of Dry Snuff

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Ariva "cigalett" pieces should be classified as a smokeless tobacco product and not a food despite containing ingredients other than tobacco such as sweeteners and natural and artificial flavorings, marketer Star Scientific contends

You may also be interested in...



Glaxo Contends FDA Ariva Decision Will Confuse Smokers Wanting To Quit

FDA's refusal to regulate Star Scientific's Ariva "cigalett" tobacco lozenges could be detrimental to the public health, GlaxoSmithKline Consumer Healthcare asserts

Glaxo Contends FDA Ariva Decision Will Confuse Smokers Wanting To Quit

FDA's refusal to regulate Star Scientific's Ariva "cigalett" tobacco lozenges could be detrimental to the public health, GlaxoSmithKline Consumer Healthcare asserts

Glaxo Contends FDA Ariva Decision Will Confuse Smokers Wanting To Quit

FDA's refusal to regulate Star Scientific's Ariva "cigalett" tobacco lozenges could be detrimental to the public health, GlaxoSmithKline Consumer Healthcare asserts
Table

View full table

Related Content

Pink Sheet HBW Insight Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS094013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By